Importantly, elevated CSF TMAO correlates with key AD pathological biomarkers, including phosphorylated tau, the p-tau/Aβ42 ratio, and neurodegeneration-associated proteins such as total tau and neurofilament light chain. This evidence concerns the gene MAPT and Alzheimer disease.